Topical pharmacotherapy for skin cancer: Part II. Clinical applications

Journal of the American Academy of Dermatology

Volumn 70, Issue 6, 2014, Pages 979.e1-979.e12

  Micali, Giuseppe ^a   Lacarrubba, Francesco ^a   Nasca, Maria Rita ^a   Ferraro, Salvatore ^a   Schwartz, Robert A ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

actinic keratosis; basal cell carcinoma; Bowen disease; erythroplasia of Queyrat; lentigo maligna; melanoma; Paget disease; skin cancer; squamous cell carcinoma; topical treatment

Indexed keywords

2,5 DIHYDROXYBENZENESULFONIC ACID; ADAPALENE; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; BETULIC ACID; BETULIN; DICLOFENAC; FLUOROURACIL; HYALURONIC ACID; IMIQUIMOD; INGENOL MEBUTATE; PIROXICAM; POTASSIUM DOBESILATE; RESIQUIMOD; RETINOIC ACID; RETINOID; TAZAROTENE; TOPICAL AGENT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ACTINIC KERATOSIS; ARTICLE; BASAL CELL CARCINOMA; BOWEN DISEASE; CHEILOSIS; DRUG EFFICACY; ERYTHROPLASIA OF QUEYRAT; EVIDENCE BASED MEDICINE; HUMAN; MALIGNANT LENTIGO; MELANOMA METASTASIS; PAGET SKIN DISEASE; PATIENT COMPLIANCE; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN CANCER; SOLAR CHEILOSIS; TREATMENT RESPONSE; TUMOR LOCALIZATION; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; COMPARATIVE STUDY; FEMALE; KERATOSIS, ACTINIC; MALE; MEDICAL EDUCATION; META ANALYSIS; MORTALITY; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; RISK ASSESSMENT; SKIN NEOPLASMS; SURVIVAL; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADMINISTRATION, TOPICAL; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS, PHASE II AS TOPIC; EDUCATION, MEDICAL, CONTINUING; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; KERATOSIS, ACTINIC; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK ASSESSMENT; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84901002749     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2013.12.037     Document Type: Review

References (112)

1. R.V. Patel, A. Frankel, and G. Goldenberg An update on nonmelanoma skin cancer J Clin Aesthet Dermatol 4 2011 20 27
2. J.F. McGuire, N.N. Ge, and S. Dyson Nonmelanoma skin cancer of the head and neck I: histopathology and clinical behaviour Am J Otolaryngol 30 2009 121 133
3. Centre for Evidence Based Medicine web site. OCEBM Levels of Evidence System. Available at: http://www.cebm.net/index.aspx?o=5653. Accessed February 22, 2014.
4. D.A. Askew, S.M. Mickan, H.P. Soyer, and D. Wilkinson Effectiveness of 5-fluorouracil treatment for actinic keratosis - a systematic review of randomized controlled trials Int J Dermatol 48 2009 453 463
5. C. Ulrich Topical treatment of field cancerization Cancer Treat Res 146 2009 439 446
6. M. Vatve, J.P. Ortonne, M.A. Birch-Machin, and G. Gupta Management of field change in actinic keratosis Br J Dermatol 157 Suppl 2 2007 21 24
7. E. Stockfleth The paradigm shift in treating actinic keratosis: a comprehensive strategy J Drugs Dermatol 11 2012 1462 1467
8. R.I. Ceilley, and J.L. Jorizzo Current issues in the management of actinic keratosis J Am Acad Dermatol 68 1 Suppl 1 2013 S28 S38
9. E. Klein, H. Milgrom, F. Helm, J. Ambrus, H.L. Traenkle, and H.L. Stoll Tumors of the skin: effects of local use of cytostatic agents Skin (Los Angeles) 1 1962 81 87
10. E. Klein, H.L. Stoll Jr., H. Milgrom, F. Helm, and M.J. Walker Tumors of the skin. XII. Topical 5-Fluorouracil for epidermal neoplasms J Surg Oncol 3 1971 331 349
11. E. Klein, H.L. Stoll, E. Miller, H. Milgrom, F. Helm, and G. Burgess The effects of 5-fluorouracil (5-FU) ointment in the treatment of neoplastic dermatoses Dermatologica 140 Suppl 1 1970 21 33
12. E. Klein, R.A. Schwartz, R.W. Case, O.A. Holtermann, J. Solomon, and G.M. Hahn et al. Accessible tumors A.F. LoBuglio, Clinical immunotherapy 1980 Marcel Dekker, Inc New York 31 71
13. S.T. McGillis, and H. Fein Topical treatment strategies for non-melanoma skin cancer and precursor lesions Semin Cutan Med Surg 23 2004 174 183
14. J.M. Weinberg Topical therapy for actinic keratoses: current and evolving therapies Rev Recent Clin Trials 1 2006 53 60
15. G. Micali, F. Lacarrubba, F. Dinotta, D. Massimino, and M.R. Nasca Treating skin cancer with topical cream Expert Opin Pharmacother 11 2010 1515 1527
16. D. Nashan, F. Meiss, and M. Müller Therapeutic strategies for actinic keratoses - a systematic review Eur J Dermatol 23 2013 14 32
17. D. de Berker, J.M. McGregor, B.R. Hughes British Association of Dermatologists Therapy Guidelines and Audit Subcommittee Guidelines for the management of actinic keratoses Br J Dermatol 156 2007 222 230
18. R.R. Kaur, A. Alikhan, and H.I. Maibach Comparison of topical 5-fluorouracil formulations in actinic keratosis treatment J Dermatolog Treat 21 2010 267 271
19. S. Amini, M.H. Viera, W. Valins, and B. Berman Nonsurgical innovations in the treatment of nonmelanoma skin cancer J Clin Aesthet Dermatol 3 2010 20 34
20. G. Hadley, S. Derry, and R.A. Moore Imiquimod for actinic keratoses: systematic review and meta-analysis J Invest Dermatol 126 2006 1251 1255
21. M.E. Falagas, A.G. Angelousi, and G. Peppas Imiquimod for the treatment of actinic keratosis: A meta-analysis of randomized controlled trials J Am Acad Dermatol 55 2006 537 538
22. E. Stockfleth, E. Christophers, B. Benninghoff, and W. Sterry Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study Arch Dermatol 140 2004 1542
23. N. Swanson, W. Abramovits, B. Berman, J. Kulp, D.S. Rigel, and S. Levy Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles J Am Acad Dermatol 62 2010 582 590
24. J.K. Rivers, J. Arlette, N. Shear, L. Guenther, W. Carey, and Y. Poulin Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel Br J Dermatol 146 2002 94 100
25. J.E. Wolf Jr., J.R. Taylor, E. Tschen, and S. Kang Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses Int J Dermatol 40 2001 709 713
26. D. Pirard, P. Vereecken, C. Mélot, and M. Heenen Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: a meta-analysis of the recent studies Arch Dermatol Res 297 2005 185 189
27. A. Pflugfelder, A.K. Welter, U. Leiter, B. Weide, L. Held, and T.K. Eigentler et al. Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group J Eur Acad Dermatol Venereol 26 2012 48 53
28. M. Lebwohl, N. Swanson, L.L. Anderson, A. Melgaard, Z. Xu, and B. Berman Ingenol mebutate gel for actinic keratosis N Engl J Med 366 2012 1010 1019
29. M. Lebwohl, S. Shumack, L.S. Gold, A. Melgaard, T. Larsson, and S.K. Tyring Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses JAMA Dermatol 149 2013 666 670
30. G. Martin, and N. Swanson Clinical findings using ingenol mebutate gel to treat actinic keratoses J Am Acad Dermatol 68 1 Suppl 1 2013 S39 S48
31. A.L. Kligman, and E.G. Thorne Topical therapy of actinic keratoses with tretinoin R. Marks, Retinoids in cutaneous malignancy 1991 Blackwell Scientific Publications Oxford, UK 66 73
32. M. Alirezai, P. Dupuy, P. Amblard, B. Kalis, P. Souteyrand, and A. Frappaz et al. Clinical evaluation of topical isotretinoin in the treatment of actinic keratoses J Am Acad Dermatol 30 1994 447 451
33. S. Kang, M.T. Goldfarb, J.S. Weiss, R.D. Metz, T.A. Hamilton, and J.J. Voorhees et al. Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial J Am Acad Dermatol 49 2003 83 90
34. R.M. Szeimies, J. Bichel, J.P. Ortonne, E. Stockfleth, J. Lee, and T.C. Meng A phase II dose-ranging study of topical resiquimod to treat actinic keratosis Br J Dermatol 159 2008 205 210
35. E. Campione, L. Diluvio, E.J. Paternò, and S. Chimenti Topical treatment of actinic keratoses with piroxicam 1% gel: a preliminary open-label study utilizing a new clinical score Am J Clin Dermatol 11 2010 45 50
36. P. Cuevas Sánchez, W. Espinoza, C. Pérez, J. Angulo, and G. Giménez-Gallego Topical treatment of actinic keratoses with potassium dobesilate 5% cream. a preliminary open-label study Eur J Med Res 16 2011 67 70
37. C. Huyke, J. Reuter, M. Rödig, A. Kersten, M. Laszczyk, and A. Scheffler et al. Treatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, comparative pilot study J Dtsch Dermatol Ges 7 2009 128 133
38. A.K. Gupta, V. Davey, and H. Mcphail Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: critical review and meta-analysis of efficacy studies J Cutan Med Surg 9 2005 209 214
39. O. Kose, E. Koc, A.H. Erbil, E. Caliskan, and Z. Kurumlu Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis J Dermatolog Treat 19 2008 159 163
40. S. Akarsu, S. Aktan, A. Atahan, P. Koç, and S. Özkan Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses Clin Exp Dermatol 36 2011 479 484
41. E. Stockfleth, H. Kerl, T. Zwingers, and C. Willers Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results Br J Dermatol 165 2011 1101 1108
42. A.K. Gupta, M. Paquet, E. Villanueva, and W. Brintnell Interventions for actinic keratoses Cochrane Database Syst Rev 12 2012 CD004415
43. Ad Hoc Task Force S.M. Connolly, D.R. Baker, B.M. Coldiron, M.J. Fazio, P.A. Storrs, and A.T. Vidimos et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery J Am Acad Dermatol 67 2012 531 550
44. L.A. Kwasniak, and J. Garcia-Zuazaga Basal cell carcinoma: evidence-based medicine and review of treatment modalities Int J Dermatol 50 2011 645 658
45. E. Klein, H.L. Stoll Jr., H. Milgrom, R.W. Case, H.L. Traenkle, and S. Graham et al. Tumors of the skin. IV. Double-blind study on effects of local administration of anti-tumor agents in basal cell carcinoma J Invest Dermatol 44 1965 351 353
46. R. Romagosa, L. Saap, M. Givens, A. Salvarrey, J.L. He, and S.L. Hsia et al. A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier Dermatol Surg 26 2000 338
47. K. Gross, L. Kircik, and G. Kricorian 5% 5-Fluorouracil cream for the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction Dermatol Surg 33 2007 433 439
48. W.B. Shelley, and M.G. Wood Nodular superficial pigmented basal cell epitheliomas. Long-term fluorouracil treatment Arch Dermatol 118 1982 928 930
49. R. Čeović, N. Smolković, A. Pašić, K. Kostović, and D. Hrsan Multiple basal cell carcinomas of lower legs with stasis dermatitis: a therapeutic challenge Acta Dermatovenerol Croat 20 2012 191 196
50. M.H. Roozeboom, A.H. Arits, P.J. Nelemans, and N.W. Kelleners-Smeets Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and non-randomized trials Br J Dermatol 167 2012 733 756
51. J.K. Geisse, P. Rich, A. Pandya, K. Gross, K. Andres, and A. Ginkel et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized vehicle-controlled study J Am Acad Dermatol 47 2002 390 398
52. H. Gollnick, C.G. Barona, R.G. Frank, T. Ruzicka, M. Megahed, and J. Maus et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe Eur J Dermatol 18 2008 677 682
53. C. Quirk, K. Gebauer, B. De'Ambrosis, H.B. Slade, and T.C. Meng Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study Cutis 85 2010 318 324
54. S. Shumack, J. Robinson, S. Kossard, L. Golitz, H. Greenway, and A. Schroeter et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens Arch Dermatol 138 2002 1165 1171
55. F. Lacarrubba, M.C. Potenza, S. Gurgone, and G. Micali Successful treatment and management of large superficial basal cell carcinomas with topical imiquimod 5% cream: a case series and review J Dermatolog Treat 22 2011 353 358
56. G. Micali, R. De Pasquale, R. Caltabiano, R. Impallomeni, and F. Lacarrubba Topical imiquimod treatment of superficial and nodular basal cell carcinomas in patients affected by basal cell nevus syndrome: a preliminary report J Dermatolog Treat 13 2002 123 127
57. G. Micali, F. Lacarrubba, M.R. Nasca, and R. De Pasquale The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin's syndrome Clin Exp Dermatol 28 Suppl 1 2003 19 23
58. R. Fallen, and M. Gooderham Ingenol mebutate: an introduction Skin Therapy Lett 17 2012 1 3
59. G. Siller, R. Rosen, M. Freeman, P. Welburn, J. Katsamas, and S.M. Ogbourne PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial Australas J Dermatol 51 2010 99 105
60. K. Peris, M.C. Fargnoli, and S. Chimenti Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma N Engl J Med 341 1999 1767 1768
61. P. Cuevas, and J.M. Arrazola Treatment of basal cell carcinoma with dobesilate J Am Acad Dermatol 53 2005 526 527
62. P. Cuevas, J. Angulo, A. Cuevas-Bourdier, I. Salgüero, and G. Giménez-Gallego Treatment of infiltrative basal cell carcinomas by inhibiting the fibroblast growth factor (FGF)-signal transducer and activator of transcription (STAT)-3 signalling pathways J Cancer Sci Ther 2011 Available at: http://dx.doi.org/10.4172/1948-5956.S3-003
63. A.H. Arits, K. Mosterd, B.A. Essers, E. Spoorenberg, A. Sommer, and M.J. De Rooij et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial Lancet Oncol 14 2013 647 654
64. T.K. Eigentler, A. Kamin, B.M. Weide, H. Breuninger, U.M. Caroli, and M. Möhrle et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma J Am Acad Dermatol 57 2007 616 621
65. F. Lacarrubba, V. D'Amico, M.R. Nasca, F. Dinotta, and G. Micali Use of dermatoscopy and videodermatoscopy in therapeutic follow up: a review Int J Dermatol 49 2010 866 873
66. G.R. Warnock, R.P. Fuller Jr., and G.B. Pelleu Jr. Evaluation of 5-fluorouracil in the treatment of actinic keratosis of the lip Oral Surg Oral Med Oral Pathol 52 1981 501 505
67. J.K. Robinson Actinic cheilitis. A prospective study comparing four treatment methods Arch Otolaryngol Head Neck Surg 115 1989 848 852
68. C. Ulrich, T. Forschner, M. Ulrich, E. Stockfleth, W. Sterry, and C. Termeer Management of actinic cheilitis using diclofenac 3% gel: a report of six cases Br J Dermatol 156 Suppl 3 2007 43 46
69. Y.T. Jadotte, and R.A. Schwartz Solar cheilosis: an ominous precursor part II. Therapeutic perspectives J Am Acad Dermatol 66 2012 187 198
70. J.P. Arlette, and M.J. Trotter Squamous cell carcinoma in situ of the skin: history, presentation, biology and treatment Austral J Dermatol 45 2004 1 11
71. H. Bargman, and J. Hochman Topical treatment of Bowen's disease with 5-fluorouracil J Cutan Med Surg 7 2003 101 105
72. A. Salim, J.A. Leman, J.H. McColl, R. Chapman, and C.A. Morton Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease Br J Dermatol 148 2003 539 543
73. G.K. Patel, R. Goodwin, M. Chawla, P. Laidler, P.E. Price, and A.Y. Finlay et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double blind, placebo-controlled trial J Am Acad Dermatol 54 2006 1025 1032
74. F. Lacarrubba, M.R. Nasca, and G. Micali Advances in the use of topical imiquimod to treat dermatologic disorders Ther Clin Risk Manag 4 2008 87 97
75. S.A. Dawe, J.R. Salisbury, and E. Higgins Two cases of Bowen's disease successfully treated topically with 3% diclofenac in 2.5% hyaluronan gel Clin Exp Dermatol 30 2005 712 713
76. M.J. Patel, and E. Stockfleth Does progression from actinic keratosis and Bowen's disease end with treatment: diclofenac 3% gel, an old drug in a new environment? Br J Dermatol 156 Suppl 3 2007 53 56
77. G. Micali, M.R. Nasca, D. Innocenzi, and R.A. Schwartz Penile cancer J Am Acad Dermatol 54 2006 369 391
78. J.W. Choi, M. Choi, and K.H. Cho A case of erythroplasia of Queyrat treated with imiquimod 5% cream and excision Ann Dermatol 21 2009 419 422
79. D.K. Goette, and T.E. Carson Erythroplasia of Queyrat: treatment with topical 5-fluorouracil Cancer 38 1976 1498 1502
80. I. Orengo, T. Rosen, and C.K. Guill Treatment of squamous cell carcinoma in situ of the penis with 5% imiquimod cream: a case report J Am Acad Dermatol 47 4 Suppl 2002 S225 S228
81. T.L. Schroeder, and R.D. Sengelmann Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream J Am Acad Dermatol 46 2002 545 548
82. G. Micali, M.R. Nasca, and R. De Pasquale Erythroplasia of Queyrat treated with imiquimod 5% cream J Am Acad Dermatol 55 2006 901 903
83. R. Hartman, J. Chu, R. Patel, S. Meehan, and J.A. Stein Extramammary Paget disease Dermatol Online J 17 2011 4
84. J.C. Zampogna, F.P. Flowers, W.I. Roth, and A.M. Hassenein Treatment of primary limited cutaneous extramammary Paget's disease with topical imiquimod monotherapy: two case reports J Am Acad Dermatol 47 Suppl 4 2002 S229 S235
85. D. Gil-Bistes, N. Kluger, V. Rigau, and B. Guillot Successful treatment of recurrent extramammary Paget's disease of the penis and scrotum with imiquimod 5% cream Presse Med 40 2011 1205 1206
86. L. Feldmeyer, K. Kerl, J. Kamarashev, P. de Viragh, and L.E. French Treatment of vulvar Paget disease with topical imiquimod: a case report and review of the literature J Dermatol Case Rep 5 2011 42 46
87. G. Baiocchi, M.D. Begnami, E.M. Fukazawa, W.S. Surima, L. Badiglian-Filho, and F.D. Costa et al. Conservative management of extramammary Paget disease with imiquimod Low Genit Tract Dis 16 2012 59 63
88. S.C. Jim On, and A.K. Izumi Extramammary Paget disease: failure to respond to topical imiquimod 5% J Am Acad Dermatol 65 2011 656 657
89. F. Toledo, J.F. Silvestre, L. Cuesta, I. Ballester, N. Latorre, and A. Monteagudo Sequential use with imiquimod and surgery in extramammary Paget's disease Dermatol Ther 25 2012 82 85
90. A.P. Bewley, A. Bracka, R.C. Staughton, and C.B. Bunker Extramammary Paget's disease of the scrotum: treatment with topical 5-fluorouracil and plastic surgery Br J Dermatol 131 1994 445 446
91. L.F. Del Castillo, C. Garcia, C. Schoendorff, J.F. Garcia, L.M. Torres, and D. Garcia Almagro Spontaneous apparent clinical resolution with histologic persistence of a case of extramammary Paget's disease: response to topical 5-fluorouracil Cutis 65 2000 331 333
92. J.N. Ye, D.C. Rhew, F. Yip, and L. Edelstein Extramammary Paget's disease resistant to surgery and imiquimod monotherapy but responsive to imiquimod combination topical chemotherapy with 5-fluorouracil and retinoic acid: a case report Cutis 77 2006 245 250
93. M.W. Bosbous, W.W. Dzwierzynski, and M. Neuburg Lentigo maligna: diagnosis and treatment Clin Plast Surg 37 2010 35 46
94. M.F. Naylor, N. Crowson, R. Kuwahara, K. Teague, C. Garcia, and C. Mackinnis et al. Treatment of lentigo maligna with topical imiquimod Br J Dermatol 149 Suppl 66 2003 66 70
95. S.F. Rajpar, and J.R. Marsden Imiquimod in the treatment of lentigo maligna Br J Dermatol 155 2006 653 656
96. G. Micali, F. Lacarrubba, B. Nardone, and M.R. Nasca Videodermatoscopy of lentigo maligna treated with imiquimod J Drugs Dermatol 7 2008 1077 1080
97. U.V. Buettiker, N.Y. Yawalkar, L.R. Braathen, and R.E. Hunger Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients Arch Dermatol 144 2008 943 945
98. M.A. Cotter, J.K. McKenna, and G.M. Bowen Treatment of lentigo maligna with imiquimod before staged excision Dermatol Surg 34 2008 147 151
99. A.M. Powell, A.M. Robson, R. Russell-Jones, and R.J. Barlow Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up Br J Dermatol 160 2009 994 998
100. J.M. Junkins-Hopkins Imiquimod use in the treatment of lentigo maligna J Am Acad Dermatol 61 2009 865 867
101. E. Nagore, and R. Botella-Estrada Imiquimod in the treatment of lentigo maligna Actas Dermosifiliogr 102 2011 559 562
102. L. Ly, J.W. Kelly, R. O'Keefe, T. Sutton, J.P. Dowling, and S. Swain et al. Efficacy of imiquimod cream, 5%, for lentigo maligna after complete excision: a study of 43 patients Arch Dermatol 147 2011 1191 1195
103. C. Erickson, and S.J. Miller Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery Int J Dermatol 49 2010 482 491
104. S. Chimenti, A.M. Carrozzo, L. Citarella, C. De Felice, and K. Peris Treatment of lentigo maligna with tazarotene 0.1% gel J Am Acad Dermatol 50 2004 101 103
105. C.S. Woodmansee, and M.W. McCall Recurrence of lentigo maligna and development of invasive melanoma after treatment of lentigo maligna with imiquimod Dermatol Surg 35 2009 1286 1289
106. G.H. Fisher, and P.G. Lang Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease Arch Dermatol 139 2003 945 947
107. K.J. Martires, L. Capaldi, S.F. Pattee, M.E. Maloney, and J.S. Bordeaux Failed treatment of amelanotic lentigo maligna with imiquimod followed by pigment production Arch Dermatol 146 2010 1047 1048
108. A. Steinmann, J.O. Funk, G. Schuler, and P. von den Driesch Topical imiquimod treatment of a cutaneous melanoma metastasis J Am Acad Dermatol 43 2000 555 556
109. G. Heber, D. Helbig, I. Pönitzsch, T. Wetzig, W. Harth, and J.C. Simon Complete remission of cutaneous and subcutaneous melanoma metastases of the scalp with imiquimod therapy J Dtsch Dermatol Ges 7 2009 534 536
110. K. Turza, L.T. Dengel, R.C. Harris, J.W. Patterson, K. White, and W.W. Grosh et al. Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis J Cutan Pathol 37 2010 94 98
111. V. Florin, E. Desmedt, S. Vercambre-Darras, and L. Mortier Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil Invest New Drugs 30 2012 1641 1645
112. K. Chitwood, J. Etzkorn, and G. Cohen Topical and intralesional treatment of nonmelanoma skin cancer: efficacy and cost comparisons Dermatol Surg 39 2013 1306 1316